Immunotherapy failure in adrenocortical cancer: where next?-Reference-Cited by-同舟云学术

Immunotherapy failure in adrenocortical cancer: where next?

Published:2018-12 Issue:12 Volume:7 Page:E5-E8
ISSN:2049-3614
Container-title:Endocrine Connections
language:
Short-container-title:

Author:

Cosentini Deborah¹,Grisanti Salvatore¹,Dalla Volta Alberto¹,Laganà Marta¹,Fiorentini Chiara²,Perotti Paola³,Sigala Sandra²,Berruti Alfredo¹

Affiliation:

1. 1Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy

2. 2Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

3. 3Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Italy

Abstract

Immunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in advanced adrenocortical carcinoma (ACC). This editorial focus on the possible mechanisms of ACC immunoevasion and suggests strategies to overcome the intrinsic immunotherapy resistance of this disease.

Publisher

Bioscientifica

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://ec.bioscientifica.com/downloadpdf/journals/ec/7/12/EC-18-0398.xml

Reference68 articles.

1. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study;Endocrine-Related Cancer,2010

2. Mitotane failure in adrenocortical cancer: where next?;Cancer,1993

3. Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options;Expert Review of Anticancer Therapy,2018

4. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;New England Journal of Medicine,2018

5. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome;Frontiers in Pharmacology,2017

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing mitotane efficacy in adrenocortical carcinoma by calcineurin inhibition with cyclosporine A;Journal of Health Sciences and Medicine;2024-07-30

2. Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinoma;European Journal of Nuclear Medicine and Molecular Imaging;2024-06-19

3. Case report: Ipilimumab and nivolumab in metastatic adrenocortical cancer with high tumor mutational burden;Frontiers in Oncology;2024-06-10

4. Histopathological analysis of tumor microenvironment in adrenocortical carcinoma: Possible effects of in situ disorganized glucocorticoid production on tumor immunity;The Journal of Steroid Biochemistry and Molecular Biology;2024-04

5. Trabectedin impairs invasiveness and metastasis in adrenocortical carcinoma preclinical models;Endocrine-Related Cancer;2023-02-01